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Abstract We describe the pre-planned interim analysis of
fracture outcomes, health-related quality of life (HRQoL)
and back pain in patients with severe osteoporosis treated
with teriparatide for up to 24 months in the Extended
Forsteo (Forsteo is a registered trade name of Eli Lilly
and Company) Observational Study (ExFOS), a prospec-
tive, multinational, observational study. Data on incident
clinical fractures, HRQoL (EQ-5D questionnaire) and back
pain [100 mm visual analogue scale (VAS)] were col-
lected. The number of patients with fractures was sum-
marised in 6-month intervals and fracture rate over each
6-month period was assessed using logistic regression for
repeated measures. Changes from baseline in EQ-5D and
back pain VAS were analysed using mixed models for
repeated measures. Of 1454 patients in the active treatment
cohort, 90.6 % were female and 14.4 % were taking glu-
cocorticoids. During teriparatide treatment (median dura-
tion 23.7 months), 103 patients (7.1 %) sustained a total of
122 incident clinical fractures (21 % vertebral, 79 % non-
vertebral). A 49 % decrease in the odds of fractures and a
75 % decrease in the odds of clinical vertebral fractures
were observed in the[18- to 24-month period versus the
first 6-month period (both p\ 0.05). EQ-5D scores and
back pain VAS scores were significantly improved from
baseline at each post-baseline observation during teri-
paratide treatment. In conclusion, patients with severe
osteoporosis showed a significant reduction in the incident
fracture rate during 24 months of teriparatide treatment in
routine clinical practice, accompanied by a significant
improvement in HRQoL and reduction in back pain.
Results should be interpreted in the context of the non-
controlled design of this observational study.
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Introduction
Osteoporosis is characterised by low bone mineral density
(BMD) and deterioration in bone quality resulting in
increased bone fragility and predisposing patients to frac-
ture. In 2010, the estimated number of people in the
European Union (EU) with osteoporosis was 27.6 million
and the annual number of new fragility fractures was 3.5
million; these included 610,000 hip fractures, 560,000
forearm fractures and 520,000 vertebral fractures [1].
Osteoporotic fractures, especially those of the hip and
vertebrae, can cause pain and functional disability, reduce
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health-related quality of life (HRQoL) [2–6], and are
associated with an increased mortality risk [7].
Teriparatide (recombinant human parathyroid hormone,
Forsteo [8]) is an osteoanabolic agent that stimulates bone
formation and improves bone quality and strength. Teri-
paratide was first approved by the European Medicines
Agency (EMA) in June 2003 for up to 18 months of
treatment in postmenopausal women with osteoporosis
after a phase III randomised controlled trial (RCT)
demonstrated that teriparatide reduces the risk of new
vertebral and non-vertebral fractures in postmenopausal
women with severe osteoporosis [9]. The reduction in the
risk of new fractures seen in the RCT was confirmed in
observational studies conducted in real-life settings, such
as the European Forsteo Observational Study (EFOS),
which showed a reduced incidence of clinical fractures,
improved HRQoL and reduced back pain during up to
18 months of treatment with teriparatide in post-
menopausal women with severe osteoporosis [10].
After the initial EMA authorisation, teriparatide
received additional approval for the treatment of osteo-
porosis in men at increased risk of fracture and for the
treatment of osteoporosis associated with sustained sys-
temic glucocorticoid (GC) therapy in men and women at
increased risk for fracture [11, 12]. More recently, the
EMA has also approved teriparatide treatment for
24 months’ total duration [8]. In the USA, the observa-
tional Direct Assessment of Non-Vertebral Fractures in
Community Experience (DANCE) study showed a reduc-
tion in non-vertebral fractures in men and women with
osteoporosis treated with teriparatide for up to 24 months
[13].
The Extended Forsteo Observational Study (ExFOS) is
a non-interventional, prospective, observational study
being conducted in Europe according to all approved
indications and the extended treatment duration during the
course of normal clinical practice. It also includes a post-
treatment follow-up of at least 18 months [14] to assess
post-teriparatide treatment patterns and effectiveness in
normal clinical practice. The objectives of this pre-planned
interim analysis of men and women with severe osteo-
porosis on active treatment with teriparatide for up to
24 months are to describe fracture outcomes, HRQoL, and
back pain.
Methods
Study Design and Patients
Patients at 110 centres in eight European countries (Croa-
tia, Denmark, France, Greece, Italy, Norway, Slovenia, and
Sweden) were enrolled in ExFOS; the study design and
baseline characteristics of the enrolled population have
previously been described [14]. The study was designed
with two phases: (1) an active treatment phase of up to
24 months during which patients were treated with teri-
paratide (which they could discontinue at any time); and
(2) an ongoing post-treatment follow-up phase after the
discontinuation of teriparatide treatment, which has a
minimum duration of 18 months. In France and Sweden,
the reimbursement of teriparatide was for 18 months only;
in the other six countries, reimbursement was for
24 months. The primary objective of the ExFOS study is to
determine the incidence of clinical vertebral and non-ver-
tebral fractures in patients treated with teriparatide. The
results presented in this paper are those from the planned
interim analysis of patients who received active treatment
for up to 24 months.
Physicians enrolled patients during routine clinical
practice. Eligible patients were judged suitable for teri-
paratide treatment, were teriparatide-treatment naı¨ve at
enrolment and were prescribed teriparatide (20 lg
administered once daily by subcutaneous self-injection) at
the baseline visit. Patients were excluded if they were
currently being treated with an investigational drug or
procedure, or if they had contraindications to teriparatide
[8]. In addition to, or after, treatment with teriparatide,
patients could be treated with any pharmacological
intervention prescribed by the physician for the treatment
of osteoporosis. Patients gave written informed consent
prior to enrolment and were able to withdraw without
consequence at any time. The study was approved by
local ethics committees or review boards, depending on
local requirements.
Data Collection and Assessments
All patient observations and data collection occurred
within the normal course of clinical care. For the active
treatment phase, data were collected at the baseline visit
and at approximately 3, 6, 12, 18, and 24 months after
starting teriparatide treatment, but physicians were not
obliged to change their usual scheduling practice for the
participating patients. For the analyses, actual patient visits
were assigned to these times according to pre-defined time
intervals.
Patient information recorded included demographics,
medical history, comorbidities and concomitant medica-
tions, lifestyle and risk factors for osteoporosis and falls,
BMD, osteoporotic fracture history (number and location),
and previous and current osteoporosis therapies. Physicians
recorded the date teriparatide treatment was started, whe-
ther reimbursement was provided for teriparatide treat-
ment, and what type of reimbursement was provided
(public or private health insurance). Patient adherence to
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teriparatide treatment was assessed at each visit by patient
self-report.
Fracture Analysis
Patients were queried at each observation about the inci-
dence of new clinical fractures, and the fracture location
and date of fracture were recorded. A new or worsened
clinical vertebral fracture was identified from the presence
of a confirmed radiographic vertebral fracture associated
with signs and/or symptoms suggestive of vertebral frac-
ture as defined by Ross [15]. The radiographic definition of
a new or worsened vertebral fracture was according to the
physicians’ clinical practice. Distinction of low- versus
high-trauma fractures was made according to the investi-
gators’ assessment of the trauma force.
Health-Related Quality of Life
HRQoL was self-assessed by patients at each visit using
the EuroQoL-5 Dimension (EQ-5D) questionnaire [16].
Patients rated their current health state in five domains
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression) scoring each domain on a 3-point
scale. From the scores, a single Health State Value (EQ-5D
HSV) was calculated based on the UK scoring algorithm
[17]. In addition, patients rated their overall health status
on the day of assessment using a visual analogue scale
(VAS; EQ-VAS) ranging from 0 (worst imaginable health
state) to 100 (best imaginable health state).
Back Pain
Back pain was self-assessed by patients at each visit using
a back pain questionnaire [10] and a 100 mm VAS, which
has been shown to be a reliable measure of pain [18].
Patients also indicated whether or not they had used anal-
gesic medication for their back pain in the past month, and
the type and frequency of analgesic medication used.
Safety
Spontaneously reported adverse events were collected
throughout the study.
Sample Size
A sample size of 1600 patients was calculated based on the
primary outcome of the study (the incidence of clinical
vertebral and non-vertebral fractures in patients treated
with teriparatide) and using an estimated drop-out rate of
30 % and an estimated incident fracture rate at 24 months
of 11 %, based on previous results from the EFOS study
[10].
Statistical Analysis
Data were analysed for the active treatment cohort, which
included all patients with baseline data who received at
least one dose of teriparatide and returned for a post-
baseline visit. All models and analyses were pre-specified
in a statistical analysis plan.
Baseline characteristics were summarised using
descriptive statistics (frequency for categorical outcomes,
and number, mean, standard deviation [SD] or median with
interquartile ranges [Q1, Q3] for continuous variables).
Incident fractures, HRQoL and back pain were sum-
marised over the teriparatide treatment period of up to
24 months. The number of fractures occurring in patients
receiving teriparatide treatment was summarised in
6-month intervals and a logistic regression with repeated
measures was used to assess the change in the proportion of
patients with one or more fractures over time, as described
previously for the EFOS study [10, 19]. The models for the
odds of fracture were adjusted for visit and the following
covariates: gender, age, prior bisphosphonate/denosumab
use and a history of vertebral or non-vertebral fracture in
the last 12 months before starting teriparatide. Contrasts
were made between the odds of fracture in the first
6 months of treatment (0–6 months) and each subsequent
6-month period. The results are presented as odds ratios
(OR), 95 % confidence intervals (95 % CI) and p values.
The fracture analyses were repeated separately for clinical
vertebral fractures, non-vertebral fractures and main non-
vertebral fractures (fractures of the forearm/wrist, hip,
humerus, leg and ribs).
A Cox proportional hazards model was used to evaluate
the effect of baseline covariates on time to first on-study
fracture. Any fractures occurring between treatment start
and 24 months were included. The results are presented as
hazard ratios (HR) and 95 % CI.
Changes from baseline in EQ-5D HSV, EQ-VAS score
and back pain VAS score were analysed using mixed
models for repeated measures (MMRM) adjusting for
selected pre-specified variables which included age, dura-
tion of prior bisphosphonate therapy, number of fractures at
baseline, fractures in the 12 months before starting teri-
paratide, and diagnosis of rheumatoid arthritis or other
rheumatological disorder. The numbers of patients report-
ing an improvement, no change or worsening in back pain
frequency, severity and limitations of activities during the
last month were analysed using the Wilcoxon signed rank
test to evaluate differences between the first visit period
and the following periods.
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All statistical analyses were performed using SAS ver-
sion 9.3 (SAS institute Inc., Cary, USA).
Results
Patient Disposition and Characteristics
Of the 1611 patients enrolled in eight European countries,
1454 patients were included in the active treatment cohort.
The remaining 157 patients did not have at least one post-
baseline visit while receiving teriparatide. The disposition
of patients in the active treatment cohort at each time point
is shown in Online Resource 1. Of the 1454 patients
included, there were 1240 reasons given for discontinua-
tion of teriparatide in 1229 patients: treatment completed
(n = 1018, 70.0 %), patient decision (n = 138, 9.5 %),
physician decision (n = 41, 2.8 %), adverse event
(n = 26, 1.8 %), death (n = 10, 0.7 %) and non-compli-
ance (n = 7, 0.5 %). At the time of this interim database
lock, teriparatide discontinuation or a reason for stopping
teriparatide treatment was not recorded for 225 patients.
The baseline demographics and clinical characteristics
of the active treatment cohort are summarised in Table 1
and were similar to the overall cohort [14]. The mean (SD)
age of the active treatment cohort at baseline was 70.2 (9.8)
years, all patients were Caucasian, 90.6 % were female,
14.4 % were taking glucocorticoids, 85.2 % had experi-
enced previous fractures, 32.0 % had sustained a vertebral
fracture in the 12 months before starting teriparatide and
88.7 % reported taking prior osteoporosis medication.
Osteoporosis Treatment
The median (Q1, Q3) and mean (SD) durations of teri-
paratide treatment were 23.7 (18.2, 24.0) months and 21.0
(4.8) months, respectively, for the 1303 patients who pro-
vided a teriparatide stop date by the time of this interim
database lock. The stop date of teriparatide treatment was
not available for 151 patients at the time of this interim
database lock.
The number and percentage of patients still taking teri-
paratide after each month are shown in Fig. 1. The decrease
in teriparatide use between 18 and 24 months occurred
mostly in the two countries where teriparatide was reim-
bursed for 18 months (i.e. France and Sweden; n = 417
patients, 28.7 % of the active treatment cohort). The mean
(SD) treatment duration for countries with 18 months’
reimbursement and 24 months’ reimbursement was 18.0
(3.6) months and 22.1 (4.8) months, respectively. During
the 24-month period, 4.2 % of patients reported one or more
treatment interruptions of longer than 4 weeks and the
median (Q1, Q3) self-reported number of missed injections
during the last month before each visit was 0 (0, 3).
After teriparatide was prescribed at the baseline visit,
combination treatment with other osteoporosis medications
was uncommon: 43 patients (3.0 %) were treated with
bisphosphonates and 13 patients (0.9 %) with non-bis-
phosphonate antiresorptives at any time from baseline until
the end of the active treatment phase. The majority of
patients continued taking calcium and vitamin D supple-
mentation (83.5 and 97 %, respectively) during teriparatide
treatment.
Fractures
Table 2 shows the incidence of clinical fractures during
teriparatide treatment for the active treatment cohort
regardless of the level of trauma. Of the 1454 patients, 103
(7.1 %) sustained a total of 122 clinical fractures between
the start and end of active treatment. Of the 103 patients
with fractures, 86 sustained a single fracture, 15 sustained
two fractures and two patients sustained three fractures. Of
the 122 fractures, 26 (21 %) were clinical vertebral frac-
tures and 96 (79 %) were non-vertebral fractures; 68
(56 %) of all fractures were main non-vertebral fractures at
the forearm/wrist (n = 31), hip (n = 12), humerus
(n = 9), leg (n = 9) or ribs (n = 7). Table 2 shows that
there was a 45 and 49 % decrease in the odds of clinical
fractures in the[12- to 18-month and[18- to 24-month
periods versus the first 6-month period, respectively
(p\ 0.05).
Over the 24-month period, 67 patients (4.6 %) sustained
a total of 77 low-trauma clinical fractures. Figure 2 pre-
sents the number (%) of patients with all clinical fractures
and clinical vertebral, non-vertebral and main non-verte-
bral fractures in each 6-month period (also see Online
Resource 2). For clinical vertebral fractures, there was a
significant reduction in the adjusted odds of fracture during
each of the teriparatide treatment periods (87 % decrease in
the[6- to 12-month period, 79 % decrease in the[12- to
18-month period and 75 % decrease in the [18- to
24-month period) compared with the first 6 months of
teriparatide treatment. The adjusted odds of non-vertebral
fractures and main non-vertebral fractures during
[6–24 months of teriparatide treatment did not differ
significantly from those in the first 6 months (Fig. 2 and
Online Resource 2).
The relative fracture risk was greater [HR = 1.59 (95 %
CI 1.07 to 2.36)] for patients with a fracture versus those
without a fracture in the 12 months before starting teri-
paratide. In addition, the relative risk of fracture was
greater [HR = 3.60 (95 % CI 1.14 to 11.42)] for female
versus male patients.
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HRQoL
The mean (SD) EQ-VAS score at baseline was 56.6 (21.2)
and the mean (SD) EQ-5D HSV at baseline was 0.50 (0.36)
with a median (Q1, Q3) of 0.62 (0.19, 0.76). The adjusted
mean changes in EQ-5D HSV and EQ-VAS score from
baseline during teriparatide treatment (Fig. 3) show sig-
nificant improvements at all post-baseline time points. In
the MMRM for EQ-VAS, several covariates had a potential
influence on the change in HRQoL: there was less
improvement if the baseline EQ-VAS score was higher
(-0.64 for each additional 1 mm; p\ 0.0001), and if the
patient was older (-0.10 for each additional year;
p\ 0.010) or had more previous fractures (-0.82 for each
additional fracture; p = 0.0002), a diagnosis of rheumatoid
arthritis or other rheumatological disorder (-2.64 compared
with no such diagnosis; p = 0.033) and fractures in the
12 months before starting teriparatide (-2.80 compared
with no fractures; p = 0.0006). Similarly, in the MMRM
for EQ-5D HSV, there was less improvement if the patient
had a lower baseline EQ-5D HSV (-0.68 for each 1 point;
95 % CI -0.72 to -0.65; p\ 0.0001), more previous
Table 1 Baseline characteristics of patients in the ExFOS active treatment cohort
Characteristic Active treatment cohort (N = 1454)
Gender (females, males), n (%) 1318 (90.6), 136 (9.4)
Age (years), mean (SD) 70.2 (9.8)
Body mass index (kg/m2), mean (SD) 25.6 (4.5)
Patients with previous fracture, n (%) 1239 (85.2)
Number of previous fractures, median (Q1, Q3) 2.0 (1.0, 3.0)
Number of previous vertebral fractures, median (Q1, Q3) 2.0 (1.0, 3.0)
Patients with fractures in the 12 months before starting teriparatide, n (%) 688 (47.3)
Patients with vertebral fractures in the 12 months before starting teriparatide, n (%) 465 (32.0)
Patients with maternal history of hip fracture, n (%) 236 (19.5)
Uses arms when standing from chair, n (%) 756 (52.3)
Sight problems, n (%) 469 (32.5)
Current smoker, n (%) 214 (14.9)
Exercises C1 h/week, n (%) 861 (60.1)
Hours of exercise/weeka, median (Q1, Q3) 4.0 (2.0, 7.0)
Has at least one alcoholic drink/week, n (%) 507 (35.7)
Number of patients with falls in previous year, n (%)
1 fall 287 (20.5)
[1 fall 256 (18.2)
Immobilised for[12 months, n (%) 45 (3.1)
Reproductive history for females (n = 1318)b
Reached menopause, n (%) 986 (98.5)
Years since onset of menopause, median (Q1, Q3) 23.0 (16.0, 29.0)
Early menopause (\40 years of age), n (%) 70 (5.8)
Surgical menopause, n (%) 137 (10.9)
Nulliparous, n (%) 147 (11.2)
Prior osteoporosis medication, n (%) 1289 (88.7)
Prior bisphosphonate use, n (%) 941 (64.7)
Duration of prior bisphosphonate therapy (months), mean (SD) 20.5 (36.6)
Current comorbidities, any disease, n (%) 487 (33.5)
Rheumatoid arthritis or other rheumatological disorder, n (%) 163 (11.2)
Taking glucocorticoids, n (%) 210 (14.4)
Percentages are based on patients with non-missing data
SD standard deviation, Q1, Q3 first and third quartile of interquartile range
a For patients who reported exercising
b Fifteen women were premenopausal
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fractures (-0.02 for each additional fracture; 95 % CI
-0.02 to-0.01; p\ 0.0001) and a diagnosis of rheumatoid
arthritis or other rheumatological disorder (-0.04 compared
with no such diagnosis; 95 % CI-0.07 to 0.00; p = 0.041).
The EQ-5D domain changes over time showing the
greatest improvements were reported in the pain/discom-
fort and usual activities domains (Online Resource 3).
Back Pain
The mean (SD) back pain VAS score at baseline was 50.1
(27.0) mm. Figure 4 shows a decrease (i.e. improvement)
in the adjusted mean change in back pain VAS from
baseline over time during up to 24 months of treatment
with teriparatide; the decrease in pain was significant at all
post-baseline assessment points, starting at 3 months. Of
the variables included in the MMRM, two had a significant
effect on the change in back pain VAS: there was a bigger
improvement (i.e. decrease) if the back pain VAS was
higher at baseline (-0.58 mm for each additional 1 mm;
95 % CI -0.62 to -0.55; p\ 0.0001); there was less
improvement if the patient had more previous fractures
(1.64 mm for each additional fracture; 95 % CI 1.04–2.24;
p\ 0.0001).
Fig. 1 Number and percentage
of patients still taking
teriparatide after each month.
a Countries with 24 months’
reimbursement for teriparatide
(Croatia, Denmark, Greece,
Italy, Norway, Slovenia). The
number above each column is
the percentage based on the
number of patients with non-
missing data (n = 960); data
regarding teriparatide
continuation missing for 77
patients. b Countries with
18 months’ reimbursement for
teriparatide (France, Sweden).
The number above each column
is the percentage based on the
number of patients with non-
missing data (n = 343); data
regarding teriparatide
continuation missing for 74
patients
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The results from the back pain questionnaire showed
that the frequency and severity of back pain and limitations
of activities and days in bed due to back pain decreased
during teriparatide treatment for up to 24 months (Online
Resource 4). At every post-baseline visit, significantly
more patients reported a decrease from baseline in the
frequency of back pain, severity of back pain and limita-
tions of activities, compared with an increase from baseline
in these measures (all p\ 0.001). The majority of patients
(75.2 %) reported taking analgesic medication for back
pain in the month before the baseline assessment. The
proportions of patients reporting analgesic use decreased to
63.5 and 58.6 % at 18 and 24 months of teriparatide
treatment, respectively. Paracetamol was the most com-
monly used analgesic medication at all time points, fol-
lowed by acetylsalicylic acid/non-steroidal anti-
inflammatory drugs, and then low-potency and high-po-
tency opiates (Online Resource 4).
Safety
Of the 1611 enrolled patients, 173 (10.7 %) had at least one
adverse event and 120 (7.4 %) had at least one serious
adverse event during the active treatment phase. Of the 339
adverse events reported, 211 (62.2 %) were serious and 57
(16.8 %) were considered possibly related to study medi-
cation. The most common adverse events ([2 %) reported
were fall (7.1 %), nausea (4.1 %) and headache (2.9 %).
No cases of osteosarcoma were observed during the
24-month teriparatide treatment phase. There were 34
patients with at least one adverse event leading to death
(2.1 % of all 1611 enrolled patients); none of these deaths
were considered related to the study drug by the reporting
investigators.
Discussion
This analysis of the active treatment phase of the ExFOS
study confirms the effectiveness of teriparatide treatment
for up to 24 months (an extra 6 months versus the origi-
nally approved 18-month treatment period in Europe) in
reducing the incidence of clinical fractures, improving
HRQoL and reducing back pain in patients with severe
osteoporosis. The risk for any clinical fracture after
[18–24 months of teriparatide treatment was reduced by
49 % compared with the first 6-month period of treatment.
Notably, the risk for clinical vertebral fractures was low
and was significantly reduced by 87 % at[6–12 months,
79 % at [12–18 months and 75 % at [18–24 months,
compared with the first 6 months of treatment. This
reduction in clinical fractures was accompanied by an
improvement in HRQoL and a reduction in back pain at all
post-baseline assessments during teriparatide treatment for
up to 24 months.
Our results are consistent with those of other observa-
tional studies of teriparatide use including the EFOS study,
which was conducted only in postmenopausal women with
severe osteoporosis who were treated with teriparatide for
up to 18 months (the approved duration for treatment in the
EU before 2009) [10]. The ExFOS study extends these
findings to other European countries (Croatia, Italy, Nor-
way and Slovenia), includes a broader range of patients
with osteoporosis [i.e. men and premenopausal women
with glucocorticoid-induced osteoporosis (GIO)] and
allowed a longer duration of teriparatide treatment of up to
24 months. However, the incidence of fractures per 10,000
patient years was lower in ExFOS (401 at 12–18 months,
436 at 18–24 months; Table 2) than in EFOS (583 at
12–18 months) [10], probably indicating a less severely
















0–6 1454 670 48 44 (3.0 %) 0.017 (0.009–0.031) – –
[6–12 1384 461 31 28 (2.0 %) 0.011 (0.006–0.021) 0.66 (0.42–1.04) 0.075
[12–18 1295 401 25 22 (1.7 %) 0.009 (0.005–0.019) 0.55 (0.33–0.92) 0.022
[18–24 1087 436 18 17 (1.6 %) 0.009 (0.004–0.018) 0.51 (0.29–0.90) 0.021
Totale 1454 122 103 (7.1 %)
CI confidence interval
a N = all patients with information regarding fractures within the time window
b As some patients experienced a fracture in more than one time interval, the total was not the sum of patients with a fracture in each interval
c Adjusted model by gender, age, prior bisphosphonate/denosumab use, and history of vertebral or non-vertebral fracture in the 12 months
before starting teriparatide
d Compared with 0- to 6-month interval
e All fractures from treatment start to end of treatment within the 24 months are included
B. L. Langdahl et al.: Fracture Rate, Quality of Life and Back Pain in Patients 265
123
osteoporotic patient population at baseline, with a lower
risk for fracture. Also, the ExFOS study included men
(n = 136) and premenopausal women with GIO (n = 15),
who have a lower risk of fractures than postmenopausal
women. The fracture baseline characteristics of the EFOS
population, reported by Rajzbaum et al. [20], would also
support the hypothesis that the ExFOS population had less
severe osteoporosis since the reimbursement criteria for
teriparatide were less strict in some of the participant
countries in the later study.
A recent observational study in patients with severe
osteoporosis referred to a specialist clinic in Scotland
found that patients treated with teriparatide (for either 18 or
24 months) had a greater increase in lumbar spine BMD
(8.2 vs. 5.0 % per year, p = 0.018) and a lower incidence
of clinical vertebral fractures (1.4 vs. 6.6 %, p = 0.011)
Fig. 2 Patients with fractures in
each 6-month interval by
fracture type. The top of each
column gives the n (%) of
patients with C1 fracture. The
OR and 95 % CI compare the
numbers of patients with C1
clinical fracture (regardless of
the level of trauma) in 6-month
intervals against the first
6 months. *p\ 0.05,
**p\ 0.01. Note as some
patients experienced more than
one type of fracture, the number
of patients for all clinical
fractures is not the sum of
patients with clinical vertebral
fractures and non-clinical
vertebral fractures. Also, as
some patients experienced a
fracture in more than one time
interval, the total was not the
sum of patients with a fracture
in each interval
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compared with patients receiving standard care (primarily
oral bisphosphonate therapy) [21]. Consistent with our
results, teriparatide treatment was associated with a
reduced risk of clinical vertebral fracture (about 88 %),
although the timescale of follow-up for teriparatide recip-
ients was longer (37.4 months) [21].
The fracture results from ExFOS can also be compared
with those from the DANCE observational study in the
USA, which used a similar analysis to evaluate the inci-
dence of new non-vertebral fragility fractures in patients
treated with teriparatide for up to 24 months [13]. In
DANCE, the incidence of new non-vertebral fractures was
significantly reduced during teriparatide treatment (to 0.91,
0.70 and 0.81 % for the[6–12 months’,[12–18 months’
and [18–24 months’ treatment periods, respectively)
compared with the first 6-month period (1.42 %) [13]. In
ExFOS, as shown in Fig. 2, the incidence of non-vertebral
fractures was also numerically reduced during teriparatide
treatment (from 2.0 % for 0–6 months, to 1.9, 1.5 and
1.3 % for [6–12, [12–18 and [18–24 months, respec-
tively), but the odds of a non-vertebral fracture during the
later time periods did not differ significantly from that in
the first 6-month period. Possible reasons for the differ-
ential findings are that the ExFOS patient cohort was much
smaller (1454 vs. 3720 patients in DANCE [13]) and that
there were differences in baseline characteristics between
the two study populations; for example, as seen in Table 1,
fewer patients in ExFOS had comorbid conditions (33.5 vs.
83.1 % patients in DANCE) [13].
Observational studies reflect routine clinical practice
and provide useful information on a larger and more
diverse group of real-world patients than those carefully
selected to participate in RCTs [22]. This includes esti-
mates of compliance and persistence with osteoporosis
therapy, which can impact on outcomes such as fracture
rates and healthcare resource use. Persistence is usually
defined as the time to treatment discontinuation or the
proportion of patients that fill a prescription without a
treatment gap of 30, 60 or 90 days [1]. In a meta-analysis
of observational studies, non-persistence with osteoporosis
therapy increased the fracture risk by 30–40 % [23]. A
recent, large-scale retrospective analysis of a US claims
Fig. 3 HRQoL: a EQ-VAS and
b EQ-5D HSV adjusted least
square mean (SE) change from
baseline. Data presented are
from MMRM analyses. Models
included change from baseline
in EQ-VAS or EQ-5D HSV as
dependent variable, visit as a
fixed repeated effect, and
baseline score (EQ-VAS or EQ-
5D HSV), age, duration of prior
bisphosphonate therapy, number
of previous fractures, fractures
in the 12 months before starting
teriparatide and diagnosis of
rheumatoid arthritis or other
rheumatological disorder as
covariates. *p\ 0.0001
compared with baseline. The
mean (SD) EQ-VAS values at
baseline 3, 6, 12, 18 and
24 months were 56.6 (21.2),
61.8 (19.6), 64.8 (19.9), 67.8
(19.1), 69.4 (19.1) and 72.3
(19.7), respectively. The mean
(SD) EQ-5D HSV scores at
baseline 3, 6, 12, 18 and
24 months were 0.50 (0.36),
0.63 (0.30), 0.68 (0.27), 0.70
(0.27), 0.74 (0.25) and 0.76
(0.24), respectively
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database showed that women noncompliant with their
osteoporosis treatment had a higher risk of fractures and
incurred higher medical costs than compliant patients [24].
As teriparatide is self-administered once daily by sub-
cutaneous injection, compliance and/or persistence may
differ from osteoporosis medications that are taken orally
or injected less frequently. Moreover, teriparatide persis-
tence has not been well-characterised beyond 12 months
among patients with severe osteoporosis and may decline
over longer periods of treatment. Analyses of claims
databases have shown an inverse relationship between
persistence with teriparatide therapy over 24 months and
fracture risk [25, 26]. Nevertheless, treatment effectively
reduces fractures after only a few months and, thereafter,
persistent patients show the lowest fracture incidence [26,
27].
More than 90 % of patients in our study were still taking
teriparatide after 12 months of treatment and a high level
of persistence was maintained during continued teri-
paratide treatment: 86 % at 17 months for countries with
18-month reimbursement and 75 % at 23 months for
countries with 24-month reimbursement (Fig. 1). The
decline in persistence between 23 and 24 months is most
likely because, in some countries with 24-month
reimbursement for teriparatide, reimbursement only covers
24 pen devices, which corresponds to 22.4 months of
treatment. The low frequency of self-reported treatment
interruptions longer than 4 weeks and of missed injections
also suggests good treatment compliance. Overall, these
results suggest that the majority of patients persist with
teriparatide treatment when it is prescribed for up to
24 months.
Also, the majority of patients being prescribed teri-
paratide in Europe have very severe osteoporosis with high
levels of back pain and disability after prior treatment with
other antiresorptive osteoporosis medications. The early
and sustained improvements in HRQoL and back pain we
observed may have had a positive effect in reinforcing
persistence with teriparatide. Moreover, the participant
countries in the study have patient support programmes in
place and, in most cases, patients are followed in spe-
cialised osteoporosis units that may facilitate adherence
and persistence to injectable therapies such as teriparatide
[28–30]. Alternatively, policies exist that involve the close
monitoring of patients at specialised osteoporosis units.
Consistent with the HRQoL results from EFOS [10,
31], patients in ExFOS had low baseline scores (EQ-5D
HSV and EQ-VAS) that improved significantly during
Fig. 4 Back pain VAS: adjusted least square mean (SE) change from
baseline. Data presented are from MMRM analysis. Model included
change from baseline in back pain VAS as dependent variable, visit as
a fixed repeated effect and baseline back pain VAS, age, duration of
prior bisphosphonate therapy, number of vertebral fractures at
baseline, vertebral fractures in the 12 months before starting
teriparatide treatment and diagnosis of rheumatoid arthritis or other
rheumatological disorder as covariates. *p\ 0.0001 compared with
baseline. The mean (SD) back pain VAS scores at baseline 3, 6, 12,
18 and 24 months were 50.1 (27.0), 41.0 (25.3), 35.4 (24.3), 31.6
(23.6), 29.7 (23.9), and 27.2 (23.5) mm, respectively
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teriparatide treatment for up to 24 months. Notably, the
steady improvement in HRQoL was maintained during
the additional 6 months of teriparatide therapy. The
changes in EQ-5D (HSV and EQ-VAS) remained signif-
icant after adjustment for various factors including age,
baseline score, previous fractures, prior bisphosphonate
use and diagnosis of rheumatoid arthritis. Improvements
were seen across all five EQ-5D domains but were
greatest in the domains of usual activities and pain/dis-
comfort. Improvements in HRQoL were smaller in older
patients and in patients with recent previous fractures or a
diagnosis of rheumatoid arthritis. This is in contrast with
EFOS, where Ljunggren et al. [31] found that the
improvement in HRQoL during teriparatide treatment was
lower in the subgroups with incident clinical fractures but
was unaffected by previous fracture in the 12 months
before starting teriparatide.
Back pain is common in patients with osteoporosis and
has been linked to the number and severity of vertebral
fractures [3, 32]. The patients taking part in ExFOS had a
high back pain VAS score at baseline (mean 50.1 mm),
reflecting the severity of their osteoporosis and the high
prevalence of vertebral fractures in the 12 months before
starting teriparatide (32 %). Nevertheless, we observed a
marked reduction in back pain VAS during teriparatide
treatment for up to 24 months. A decrease of 10 mm in
back pain VAS is considered a clinically significant
reduction [33], and this was exceeded by the 3-month
observation in ExFOS; Fig. 4 shows the decrease in back
pain VAS had reached 23 mm by 24 months. As seen in
Fig. 4, there was a continued reduction in back pain from
baseline during the extra 6 months of teriparatide therapy
(months 18–24). This was accompanied by reductions in
the frequency and severity of back pain, and activity lim-
itations and days in bed due to back pain, together with
self-reported reductions in the use of analgesics for back
pain. An earlier study [34] and a meta-analysis [35] found a
reduced incidence of new or worsening back pain in teri-
paratide-treated patients, which may have been associated
with a reduction in vertebral fractures [34]. Among post-
menopausal women with severe osteoporosis who received
teriparatide for 2 years in the EUROFORS study, there was
a rapid and significant reduction in back pain in both
subgroups of patients with and without a vertebral fracture
in the 12 months before baseline, despite the high pain
level (mean baseline back pain VAS was 54.8 mm with vs.
45.8 mm without a recent vertebral fracture) [36].
The adverse events spontaneously reported during teri-
paratide treatment were consistent with the current label
information. Notably, there were no cases of osteosarcoma,
a rare bone cancer found previously in preclinical studies
of rats exposed to teriparatide for 2 years [37]. This is in
agreement with the findings from post-marketing surveil-
lance studies in the USA and five Nordic countries, which
failed to identify a causal association between teriparatide
treatment and osteosarcoma in humans [38, 39]. Moreover,
a retrospective longitudinal cohort study using Danish
nationwide registers, which included 4104 subjects,
reported that osteosarcoma has not been diagnosed in any
Danish patient receiving teriparatide since it was intro-
duced on the market in 2003 [40].
Several study limitations have to be taken into account
when interpreting the current findings. Notably, this was an
observational study in a naturalistic setting and the data
collected by patient self-report (including fracture data)
may be subject to recall bias. Also, the duration of teri-
paratide therapy varied as a consequence of the reim-
bursement criteria for different countries: teriparatide was
only reimbursed for 18 months in France and Sweden
(n = 417 patients; 28.7 % of the active treatment cohort)
and 24 months in the other participating countries. Finally,
patients were not evenly distributed across the participating
countries and previous research has shown that there is a
marked difference in the incidence of fractures between
countries [1].
The strengths of the ExFOS study include the observa-
tional study design that comprised a broad population of
patients with severe osteoporosis according to the approved
European label. This allowed us to gather longitudinal data
in patients treated with teriparatide in real-life clinical
practice, making the results applicable to the general
population in Europe. Also, our pre-defined analyses
adjusted for factors that might influence the risk for frac-
ture, including age, duration of prior bisphosphonate ther-
apy, previous fractures and comorbid rheumatological
disorders.
In conclusion, this analysis of the active treatment phase
of the ExFOS study shows that men and women with
severe osteoporosis treated with teriparatide in routine
clinical practice experience a significant reduction in
incident fracture rate over 18–24 months of teriparatide
treatment. This is accompanied by a significant improve-
ment in HRQoL and a significant reduction in back pain.
Safety was consistent with the current prescribing infor-
mation for teriparatide. Although our findings should be
interpreted in the context of the open-label, non-controlled
design of the study, they indicate that teriparatide is an
effective treatment for patients with osteoporosis for up to
24 months in routine clinical practice. Further results from
the post-teriparatide follow-up period of the study will be
reported at a later date.
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